Clinical trials: Acne Inversa
Pharmacokinetics, Safety Issues
A Clinical Study With Adalimumab Biosimilar
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs.
- Trial name
- NCT06291948
- Testing
- Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product]
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Hidradenitis Suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- RECHARGE-2 (NCT06840392)
- Testing
- Remibrutinib Dose A, Remibrutinib Dose B
- Where
- 129 sites in United States, Argentina and 17 more
- Volunteers
- 565 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
This was a Phase 2 study in adult participants with moderate to severe hidradenitis suppurativa (HS). The purpose of the study was to evaluate the efficacy and safety of SAR442970 compared to placebo.
- Trial name
- HS OBTAIN (NCT05849922)
- Testing
- SAR442970
- Where
- 45 sites in United States, Australia and 13 more
- Volunteers
- 86 people
- Sponsor
- Sanofi
Hidradenitis Suppurativa
Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
A study to explore the safety and efficacy of treatment with BDB-001 Injection in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT05103423
- Testing
- BDB-001 Injection
- Where
- 15 sites in China
- Volunteers
- 50 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER I (NCT01468207)
- Testing
- adalimumab
- Volunteers
- 307 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hidradenitis Suppurativa
This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week…
- Trial name
- SUNSHINE (NCT03713619)
- Testing
- secukinumab
- Where
- 111 sites in United States, Argentina and 27 more
- Volunteers
- 544 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
The purpose of this study is to assess the safety of INCB054707 in men and women with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT03569371
- Testing
- INCB054707
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa (HS)
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal and genital) regions.
- Trial name
- NCT04430855
- Testing
- Upadacitinib
- Where
- 26 sites in United States, Canada and 2 more
- Volunteers
- 68 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa
Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa
This is a randomized, double-blind, placebo-controlled, parallel-group phase 1b study to evaluate AT193 in approximately 44 participants with HS. The treatment period will be 8 weeks followed by a 2-week nontreatment follow-up.
- Trial name
- NCT04989517
- Testing
- AT193
- Where
- 7 sites in Australia
- Volunteers
- 49 people
- Sponsor
- Azora Therapeutics Australia Pty Ltd
Hidradenitis Suppurativa (HS)
Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SCT650C in patients with Moderate to Severe Hidradenitis Suppurativa
- Trial name
- NCT07244510
- Testing
- SCT650C
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Sinocelltech Ltd.
Hidradenitis
Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This is a parallel, Phase 2, 2-arm, double-blind, randomized, multicenter, multinational, placebo-controlled study to evaluate efficacy, safety, pharmacokinetics (PK), and biological effects of treatment of subcutaneous injection…
- Trial name
- NCT06118099
- Testing
- Amlitelimab
- Where
- 42 sites in United States, Australia and 9 more
- Volunteers
- 90 people
- Sponsor
- Sanofi
Hidradenitis Suppurativa
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
The main purpose of this study is to assess preliminary efficacy and safety of CFZ533/iscalimab (Cohort A), LYS006 (Cohort B), MAS825 (Cohort C), LOU064/remibrutinib (Cohort D) and VAY736/ianalumab (Cohort E) in patients with…
- Trial name
- NCT03827798
- Testing
- CFZ533, LYS006, MAS825
- Where
- 36 sites in United States, Austria and 9 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS), is a chronic skin disease, manifested as inflamed areas of hair follicles around apocrine sweat glands found in areas most commonly the axillae, inguinal and anogenital regions.
- Trial name
- NCT03929835
- Testing
- Cannabis oil
- Where
- Israel
- Sponsor
- TO Pharmaceuticals
Hidradenitis Suppurativa (HS)
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa
This study is a Phase Ic/II clinical trial conducted in Chinese patients with moderate-to-severe hidradenitis suppurativa (HS), aiming to evaluate the safety and efficacy of LT-002-158 tablets in the treatment of…
- Trial name
- NCT06932003
- Testing
- LT-002-158 Tablets
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Hidradenitis Suppurativa
Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation
The primary objective of this non-interventional study is to describe the evolution of Hidradenitis suppurativa (HS) symptoms 12 months after secukinumab initiation based on the patients' assessment of pain, oozing, and bad smell.
- Trial name
- SPECTRA (NCT06444087)
- Testing
- secukinumab
- Where
- 22 sites in France
- Volunteers
- 192 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent…
- Trial name
- STOP-HS LTE (NCT06212999)
- Testing
- Povorcitinib
- Where
- 165 sites in United States, Australia and 15 more
- Volunteers
- 617 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- BE HEARD II (NCT04242498)
- Testing
- Bimekizumab
- Where
- 91 sites in United States, Australia and 12 more
- Volunteers
- 509 people
- Sponsor
- UCB Biopharma SRL
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab in adult participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NOVA (NCT03628924)
- Testing
- Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3
- Where
- 45 sites in United States, Canada and 4 more
- Volunteers
- 184 people
- Sponsor
- Janssen Research & Development, LLC
Hidradenitis Suppurativa (HS)
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
- Trial name
- NCT07213973
- Testing
- Povorcitinib
- Where
- 30 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Incyte Corporation
Hidradenitis, Healthy Volunteers
SAR447971 First-in-human Study
SAD20411 is a single-center, first-in-human, double-blind, randomized, placebo-controlled, sequential single ascending dose study in healthy male and/or female participants with a pilot food effect investigation.
- Trial name
- NCT07629336
- Testing
- SAR447971
- Where
- Netherlands
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Sanofi